Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
3.210
+0.020 (0.63%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Niagen Bioscience Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Niagen Bioscience stock has a consensus rating of "Strong Buy" and an average price target of $11.83. The average 1-year stock price forecast is 268.54% higher than the current stock price, while the lowest is $9.00 (+180.37%) and the highest is $18 (+460.75%).
Price Target: $11.83 (+268.54%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Niagen Bioscience stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $11 | Buy | Reiterates | $11 | +242.68% | Jul 9, 2026 |
| Freedom Capital Markets | Freedom Capital Markets | Buy Initiates $9 | Buy | Initiates | $9 | +180.37% | Jul 6, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $10 | Buy | Maintains | $10 | +211.53% | May 28, 2026 |
Unknown Analyst Ladenburg Thalmann & Co. No rating | Ladenburg Thalmann & Co. | Buy Reiterates $12 | Buy | Reiterates | $12 | +273.83% | May 7, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $13 → $12 | Buy | Reiterates | $13 → $12 | +273.83% | May 7, 2026 |
Financial Forecast
Revenue This Year
141.37M
from 129.42M
Increased by 9.23%
Revenue Next Year
165.06M
from 141.37M
Increased by 16.76%
EPS This Year
0.19
from 0.17
Increased by 13.50%
EPS Next Year
0.29
from 0.19
Increased by 52.63%
EPS and Forward PE are based on non-GAAP adjusted numbers.